Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000921895-17-001972
Filing Date
2017-07-24
Accepted
2017-07-24 17:09:58
Documents
3

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D sc13d10959006_07242017.htm SC 13D 115556
2 LETTER AGREEMENT ex994to13d10959006_072417.htm EX-99.4 56654
3 JOINT FILING AGREEMENT ex995to13d10959006_072417.htm EX-99.5 4776
  Complete submission text file 0000921895-17-001972.txt   178573
Mailing Address 1275 WEST WASHINGTON STREET SUITE 101 TEMPE AZ 85281
Business Address 1275 WEST WASHINGTON STREET SUITE 101 TEMPE AZ 85281 6022865520
Capstone Therapeutics Corp. (Subject) CIK: 0000887151 (see all company filings)

EIN.: 860585310 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-42745 | Film No.: 17978819
SIC: 2834 Pharmaceutical Preparations

Mailing Address 122 EAST 42ND STREET SUITE 4305 NEW YORK NY 10168
Business Address 122 EAST 42ND STREET SUITE 4305 NEW YORK NY 10168 212-302-0699
BP Peptides, LLC (Filed by) CIK: 0001711689 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: SC 13D